Ilexgenin A inhibits endoplasmic reticulum stress and ameliorates endothelial dysfunction via suppression of TXNIP/NLRP3 inflammasome activation in an AMPK dependent manner

Pharmacol Res. 2015 Sep:99:101-15. doi: 10.1016/j.phrs.2015.05.012. Epub 2015 Jun 6.

Abstract

Ilexgenin A is a natural triterpenoid with beneficial effects on lipid disorders. This study aimed to investigate the effects of ilexgenin A on endothelial homeostasis and its mechanisms. Palmitate (PA) stimulation induced endoplasmic reticulum stress (ER stress) and subsequent thioredoxin-interacting protein (TXNIP)/NLRP3 inflammasome activation in endothelial cells, leading to endothelial dysfunction. Ilexgenin A enhanced LKB1-dependent AMPK activity and improved ER stress by suppression of ROS-associated TXNIP induction. However, these effects were blocked by knockdown of AMPKα, indicating AMPK is essential for its action in suppression of ER stress. Meanwhile, ilexgenin A inhibited NLRP3 inflammasome activation by down-regulation of NLRP3 and cleaved caspase-1 induction, and thereby reduced IL-1β secretion. It also inhibited inflammation and apoptosis exposed to PA insult. Consistent with these results in endothelial cells, ilexgenin A attenuated ER stress and restored the loss of eNOS activity in vascular endothelium, and thereby improved endothelium-dependent vasodilation in rat aorta. A further analysis in high-fat fed mice showed that oral administration of ilexgenin A blocked ER stress/NLRP3 activation with reduced ROS generation and increased NO production in vascular endothelium, well confirming the beneficial effect of ilexgenin A on endothelial homeostasis in vivo. Taken together, these results show ER stress-associated TXNIP/NLRP3 inflammasome activation was responsible for endothelial dysfunction and ilexgenin A ameliorated endothelial dysfunction by suppressing ER-stress and TXNIP/NLRP3 inflammasome activation with a regulation of AMPK. This finding suggests that the application of ilexgenin A is useful in the management of cardiovascular diseases in obesity.

Keywords: AICA riboside (PubChem CID: 17513); AMPK; Acetylcholine (PubChem CID: 75271); BAPTA-AM (PubChem CID: 2293); Compound C (PubChem CID: 11524144); Dimethyl sulfoxide (PubChem CID: 679); Endoplasmic reticulum stress; Endothelial dysfunction; Ilexgenin A; Mitoquinone mesylate (PubChem CID: 11388331); NLRP3 inflammasome; Palmitic acid (PubChem CID: 985); Phenylephrine (PubChem CID: 5284443); Tauroursodeoxycholic acid (PubChem CID: 46782978); Thapsigargin (PubChem CID: 446378).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / deficiency
  • AMP-Activated Protein Kinases / genetics
  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / metabolism
  • Apoptosis / drug effects
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / metabolism
  • Carrier Proteins / metabolism
  • Caspase 3 / metabolism
  • Cell Line
  • Drugs, Chinese Herbal / pharmacology
  • Endoplasmic Reticulum Stress / drug effects*
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism*
  • Gene Knockdown Techniques
  • Humans
  • Ilex
  • Inflammasomes / drug effects
  • Inflammasomes / metabolism
  • Lipid Metabolism / drug effects
  • Male
  • Mice
  • Mice, Inbred ICR
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism
  • Thioredoxins / metabolism
  • Triterpenes / pharmacology*

Substances

  • Carrier Proteins
  • Drugs, Chinese Herbal
  • Inflammasomes
  • Reactive Oxygen Species
  • Triterpenes
  • ilexgenin A
  • Thioredoxins
  • AMP-Activated Protein Kinases
  • Caspase 3